In order to evaluate whether the reactivation of FRK expression in breast cancer cells by epigenetic drugs was associated with promoter CpG demethylation, BT549 and Hs578T were evaluated after 5 days of 24 hourly treatments with DAC, and in the BT549, 24 hours post-treatment with Entinostat (Figure 5A). Here, FRK is linked to breast carcinoma.